stk1-ligand

Recombinant proteinexperimental

Clinical trial activity

5 trials · 10 clinical orgs · 0 marketing orgs

Phase 1
4
Phase 2
2
Phase 3
1
Phase 4
0

Earliest trial started Jun 1, 1998 (NCT00003431)

Timeline

1990s

  1. Jan 1, 1998

    Earliest Phase 1 Sponsor(trial)

2000s

  1. Jan 1, 2000

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Also known as

  • flk2-flt3 ligand
  • flk2 ligand
  • flt-3 ligand
  • flt3 ligand
  • flt3 ligand
  • flt3 ligand protein
  • fms-like tyrosine kinase 3 ligand
  • mobista
  • stem cell tyrosine kinase 1 ligand
  • stk1-ligand

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT00020540Phase 1Mar 1, 2001National Cancer Institute (NCI), National Institutes of Health (NIH)
NCT00006223Phase 3Jul 1, 2000Cancer and Leukemia Group B (CALGB), Eastern Cooperative Oncology Group, Loyola University, National Cancer Institute (NCI), Southwest Oncology Group, Technion University, University of Chicago
NCT00006225Phase 1/Phase 2 (Phase 2)Nov 1, 1999Northwestern University
NCT00005787Phase 1Sep 1, 1999National Cancer Institute (NCI), Northwestern University
NCT00003431Phase 1Jun 1, 1998Duke University, National Cancer Institute (NCI)
Showing 5 of 5 trials
Page 1 / 1

Organizations

Research & Development (10)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Cancer Institute (NCI)Government4121998
Northwestern UniversityAcademic/Hospital2221999
Cancer and Leukemia Group B (CALGB)Academic/Hospital1012000
Duke UniversityAcademic/Hospital1111998
Eastern Cooperative Oncology GroupAcademic/Hospital1112000
Loyola UniversityAcademic/Hospital1012000
National Institutes of Health (NIH)Government1012001
Southwest Oncology GroupAcademic/Hospital1012000
Technion UniversityAcademic/Hospital1012000
University of ChicagoAcademic/Hospital1012000
10 organizations
Page 1 / 1